Literature DB >> 6533293

Absence of a significant pharmacokinetic interaction between hydrochlorothiazide and triamterene when coadministered.

R A Upton, R L Williams, E T Lin, W L Gee, C D Blume, L Z Benet.   

Abstract

Hydrochlorothiazide, triamterene, and hydroxytriamterene sulfate were monitored in the plasma and urine of 24 healthy young men taking single doses of a liquid preparation containing both hydrochlorothiazide and triamterene, liquid preparations containing either of these drugs alone, and a combination tablet recently formulated with a dose ratio of hydrochlorothiazide : triamterene (1 : 1.5) found to give optimal potassium-sparing effect. In contradiction to a recent publication, no interaction between the drugs affecting the bioavailability or renal clearance of either could be demonstrated. The previous report of drug-drug interaction probably arose from formulation-related problems with bioavailability from the two capsule and two tablet products which had been studied. A well-formulated hydrochlorothiazide-triamterene combination tablet promotes plasma concentrations and urinary excretion of hydrochlorothiazide, triamterene, and hydroxytriamterene sulfate which are virtually identical to those seen after either a combination liquid dosage form or simple liquid forms containing only one of the two drugs.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6533293     DOI: 10.1007/bf01059553

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  8 in total

1.  The influence of dosage form on the activity of a diuretic agent.

Authors:  P J Tannenbaum; E Rosen; T Flanagan; A P Crosley
Journal:  Clin Pharmacol Ther       Date:  1968 Sep-Oct       Impact factor: 6.875

2.  Potassium-sparing effects of triamterene in the treatment of hypertension.

Authors:  R E Spiekerman; K G Berge; D L Thurber; S W Gedge; W F McGuckin
Journal:  Circulation       Date:  1966-09       Impact factor: 29.690

3.  Liquid chromatographic analysis of triamterene and its major metabolite, hydroxytriamterene sulfate, in blood, plasma, and urine.

Authors:  F Sörgel; E T Lin; J Hasegawa; L Z Benet
Journal:  J Pharm Sci       Date:  1984-06       Impact factor: 3.534

Review 4.  Clinical pharmacokinetics of diuretics.

Authors:  B Beermann; M Groschinsky-Grind
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

5.  Changes in serum potassium levels occurring in patients treated with triamterene and a triamterene-hydrochlorothiazide combination.

Authors:  K B Hansen; A D Bender
Journal:  Clin Pharmacol Ther       Date:  1967 May-Jun       Impact factor: 6.875

6.  Preliminary observations on dissolution and bioavailability of triamterene-hydrochlorothiazide combination products.

Authors:  V P Shah; M A Walker; V K Prasad; J Lin; G Knapp; B E Cabana
Journal:  Biopharm Drug Dispos       Date:  1984 Jan-Mar       Impact factor: 1.627

7.  Pharmacokinetics of hydrochlorothiazide in relation to renal function.

Authors:  C Niemeyer; G Hasenfuss; U Wais; H Knauf; M Schäfer-Korting; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Bioequivalence study of a new tablet formulation of triamterene and hydrochlorothiazide.

Authors:  C D Blume; R L Williams; R A Upton; E T Lin; L Z Benet
Journal:  Am J Med       Date:  1984-11-05       Impact factor: 4.965

  8 in total
  2 in total

1.  Comparison of the diuretic effect and absorption of a single dose of furosemide and free and the fixed combinations of furosemide and triamterene in healthy male adults.

Authors:  J J van Meyel; Y Tan; P Smits; F G Russel; C A van Ginneken; F W Gribnau
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Effects of formulation and food on the absorption of hydrochlorothiazide and triamterene or amiloride from combination diuretic products.

Authors:  R L Williams; J Mordenti; R A Upton; E T Lin; W L Gee; C D Blume; L Z Benet
Journal:  Pharm Res       Date:  1987-08       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.